Afuco™ Anti-Human CMV ADCC Therapeutic Antibody (TCN-202), ADCC Enhanced
Anti-CMV ADCC Enhanced Antibody (TCN-202) is an ADCC enhanced antibody produced by our Afuco™ platform. TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection. TCN-202 is directed against a universal target within CMV variations, and this Phase 1 study is a significant step in bringing an important new treatment to patients with CMV infection.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-169CL |
| Pricing | Inquiry |
| Host | Human |
| Target | CMV |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at -20°C for long-term storage. Store at 4°C for up to one month. Avoid freeze/thaw cycles. |